Stock Events

Stock Events

Wuhan YZY Biopharma. 

HK$3.50
1
+HK$0.00+0%Tuesday 01:30

Statistics

Day High
3.5
Day Low
3.5
52W High
8.4
52W Low
2.2
Volume
1,200
Avg. Volume
73
Mkt Cap
678.47M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-126.47%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
73.76MRevenue
-93.28MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Wenye Group Limited
1802.HK
Mkt Cap427.68M
Innovent Biologics specializes in the development and manufacturing of monoclonal antibodies, directly competing in the biopharmaceutical sector with Wuhan YZY Biopharma.
Wuxi Biologics (Cayman)
2269.HK
Mkt Cap219B
WuXi Biologics offers comprehensive integrated services across the biopharmaceutical development continuum, competing with Wuhan YZY Biopharma in the biopharma outsourcing space.
Hansoh Pharmaceutical Group Company Limited
3692.HK
Mkt Cap90.49B
JW Therapeutics focuses on cell-based immunotherapy, competing with Wuhan YZY Biopharma in the innovative biopharma and cell therapy sector.
Ascletis Pharma
1672.HK
Mkt Cap3.89B
CStone Pharmaceuticals is engaged in the discovery and development of novel drugs, directly competing with Wuhan YZY Biopharma in the oncology and immunology fields.
CanSino Biologics
6185.HK
Mkt Cap35.2B
Mabpharm specializes in the development of biologic drugs, including monoclonal antibodies, posing direct competition to Wuhan YZY Biopharma's core business areas.
Lifestyle China Group Limited
2136.HK
Mkt Cap1.27B
Zai Lab focuses on bringing transformative medicines for cancer, autoimmune and infectious diseases, competing in the same therapeutic areas as Wuhan YZY Biopharma.
Genscript Biotech
1548.HK
Mkt Cap49.16B
Genor Biopharma is involved in the development of biologic drugs in the fields of oncology and autoimmune diseases, areas where Wuhan YZY Biopharma is also active.
Akeso
9926.HK
Mkt Cap33.77B
RemeGen focuses on developing innovative biologics in the areas of autoimmune, oncology, and ophthalmic diseases, competing with Wuhan YZY Biopharma in multiple therapeutic areas.

About

Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Show More
CEO
Pengfei Zhou
Employees
106
Country
China
ISIN
CNE1000063C4

Listings

HK
HK
2496.HK

0 Comments

Share your thoughts

FAQs

What is Wuhan YZY Biopharma. stock price today?▼
The current price of 2496.HK is HK$3.50 HKD — it has increased by +0% in the past 24 hours. Watch Wuhan YZY Biopharma. stock price performance more closely on the chart.
What is Wuhan YZY Biopharma. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Hong Kong Exchange exchange Wuhan YZY Biopharma. stocks are traded under the ticker 2496.HK.
Is Wuhan YZY Biopharma. stock price growing?▼
2496.HK stock has risen by +0% compared to the previous week, the month change is a +9.37% rise, over the last year Wuhan YZY Biopharma. has showed a -50.07% decrease.
What is Wuhan YZY Biopharma. market cap?▼
Today Wuhan YZY Biopharma. has the market capitalization of 678.47M
What is Wuhan YZY Biopharma. revenue for the last year?▼
Wuhan YZY Biopharma. revenue for the last year amounts to 73.76M HKD.
What is Wuhan YZY Biopharma. net income for the last year?▼
2496.HK net income for the last year is -93.28M HKD.
How many employees does Wuhan YZY Biopharma. have?▼
As of November 3, 2026, the company has 106 employees.
In which sector is Wuhan YZY Biopharma. located?▼
Wuhan YZY Biopharma. operates in the Health & Wellness sector.
When did Wuhan YZY Biopharma. complete a stock split?▼
Wuhan YZY Biopharma. has not had any recent stock splits.
Where is Wuhan YZY Biopharma. headquartered?▼
Wuhan YZY Biopharma. is headquartered in Wuhan, China.